A common molecular pathway could help physicians predict which lung cancer patients will benefit from chemotherapy drugs, according to new research from a multidisciplinary team at the University of Cincinnati (UC).

A new technique could pave the way toward screening people at risk for lung cancer for the genetic changes that may foreshadow malignancies, researchers from the University of Colorado say.

A Queensland scientist has won a $750,000 fellowship to develop a lung cancer treatment from a bacterium found in eastern grey kangaroos. The State Government presented the award to University of Queensland researcher Dr Ming Wei.

A pattern of gene expression might be able to identify which stage I lung cancer patients have the poorest prognosis.

Collaborating scientists in Boston and North Carolina have found that a particular gene can block key steps of the lung cancer process in mice. The researchers report in the journal Nature that LKB1 is not only a "tumor-suppressor" gene for non-small cell lung cancer in mice, it also may be more powerful than other, better-known suppressors. The study will be published on the journal's Web site on Aug. 5 and later in a print version.

Variations in two genes related to inflammation may be a major risk factor for developing lung cancer, according to a team of scientists from the National Cancer Institute and the University of Texas M. D. Anderson Cancer Center.

Patients with inoperable non-small cell lung cancer who receive an initial high dose of chemotherapy before their treatment begins can expect an increase in overall survival, according to a study in the July 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.

Talcum powder has been used for generations to soothe babies' diaper rash and freshen women's faces. But University of Florida researchers report the household product has an additional healing power: The ability to stunt cancer growth by cutting the flow of blood to metastatic lung tumors.

A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has discovered a "signature" of proteins in the blood that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies.

In the first scientific study of its kind, shark cartilage extract, AE-941 or Neovastat, has shown no benefit as a therapeutic agent when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer, according to researchers at The University of Texas M. D. Anderson Cancer Center.

Any number of things can go wrong in the cells of the body to cause cancer -- and clinicians can't tell by just looking at a tumor what exactly triggered the once normal cells to turn cancerous.

Statistics show lung cancer is the leading cause of cancer death in African-Americans, with 21,550 new cases expected to be diagnosed and 16,700 deaths expected this year. Equally devastating, lung cancer is the leading cause of cancer death in Hispanic men and the second leading cause of cancer death in Hispanic women.